| Dr John Joseph Grechus, MD | |
|
1103 Weber Rd Ste 203, Farmington, MO 63640-3302 | |
| (573) 756-9107 | |
| (573) 756-9630 |
| Full Name | Dr John Joseph Grechus |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 41 Years |
| Location | 1103 Weber Rd Ste 203, Farmington, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831171560 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | R5F25 (Missouri) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Great Mines Health Center | 3072598143 | 15 |
News Archive
CQ HealthBeat: "The medical device industry told the Centers for Medicare and Medicaid Services that it's concerned about whether accountable care organizations could give providers financial incentives to hold back on needed patient care, particularly on technology. Meanwhile, insurance plan executives warned CMS officials that the ACOs could give hospitals and doctors new bargaining leverage in negotiations with insurers.
In a recent bioRxiv paper, researchers from Norway and the US demonstrate the presence of a highly conserved, mobile genetic element (thus far with unknown function) in genomes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a large number of insects – opening the door for hitherto unexplored treatment opportunities.
ThermalTherapeutic Systems, Inc., developers of a highly portable platform technology to standardize hyperthermic perfusion announced today the completion of $2.75 Million Series A financing.
Allergan, Inc. ("Allergan" or the "Company") today became aware of public filings made by Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") regarding Valeant's purported intention to propose a merger in which the Company's stockholders would receive a combination of Valeant common shares and cash in exchange for the outstanding shares of the Company's common stock.
Cubist Pharmaceuticals, Inc. today announced that its currently-marketed antibiotic, CUBICIN (daptomycin for injection), has been approved by the U.S. Food & Drug Administration (FDA) for once-a-day dosing as a 2-minute intravenous (IV) injection.
› Verified 1 days ago
| Entity Name | Great Mines Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376536953 PECOS PAC ID: 3072598143 Enrollment ID: O20041004000035 |
News Archive
CQ HealthBeat: "The medical device industry told the Centers for Medicare and Medicaid Services that it's concerned about whether accountable care organizations could give providers financial incentives to hold back on needed patient care, particularly on technology. Meanwhile, insurance plan executives warned CMS officials that the ACOs could give hospitals and doctors new bargaining leverage in negotiations with insurers.
In a recent bioRxiv paper, researchers from Norway and the US demonstrate the presence of a highly conserved, mobile genetic element (thus far with unknown function) in genomes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a large number of insects – opening the door for hitherto unexplored treatment opportunities.
ThermalTherapeutic Systems, Inc., developers of a highly portable platform technology to standardize hyperthermic perfusion announced today the completion of $2.75 Million Series A financing.
Allergan, Inc. ("Allergan" or the "Company") today became aware of public filings made by Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") regarding Valeant's purported intention to propose a merger in which the Company's stockholders would receive a combination of Valeant common shares and cash in exchange for the outstanding shares of the Company's common stock.
Cubist Pharmaceuticals, Inc. today announced that its currently-marketed antibiotic, CUBICIN (daptomycin for injection), has been approved by the U.S. Food & Drug Administration (FDA) for once-a-day dosing as a 2-minute intravenous (IV) injection.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Joseph Grechus, MD 1103 Weber Rd Ste 203, Farmington, MO 63640-3302 Ph: (573) 756-9107 | Dr John Joseph Grechus, MD 1103 Weber Rd Ste 203, Farmington, MO 63640-3302 Ph: (573) 756-9107 |
News Archive
CQ HealthBeat: "The medical device industry told the Centers for Medicare and Medicaid Services that it's concerned about whether accountable care organizations could give providers financial incentives to hold back on needed patient care, particularly on technology. Meanwhile, insurance plan executives warned CMS officials that the ACOs could give hospitals and doctors new bargaining leverage in negotiations with insurers.
In a recent bioRxiv paper, researchers from Norway and the US demonstrate the presence of a highly conserved, mobile genetic element (thus far with unknown function) in genomes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a large number of insects – opening the door for hitherto unexplored treatment opportunities.
ThermalTherapeutic Systems, Inc., developers of a highly portable platform technology to standardize hyperthermic perfusion announced today the completion of $2.75 Million Series A financing.
Allergan, Inc. ("Allergan" or the "Company") today became aware of public filings made by Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") regarding Valeant's purported intention to propose a merger in which the Company's stockholders would receive a combination of Valeant common shares and cash in exchange for the outstanding shares of the Company's common stock.
Cubist Pharmaceuticals, Inc. today announced that its currently-marketed antibiotic, CUBICIN (daptomycin for injection), has been approved by the U.S. Food & Drug Administration (FDA) for once-a-day dosing as a 2-minute intravenous (IV) injection.
› Verified 1 days ago
Mr. John David Edward Cooper, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1103 W Liberty St, Farmington, MO 63640 Phone: 573-756-6751 Fax: 573-756-6807 | |
Joan Azoury, M.D Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1103 W Liberty St, Farmington, MO 63640 Phone: 573-756-6751 | |
Dr. Luis R Mertins, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1103 W Liberty St, Farmington, MO 63640 Phone: 573-756-6751 Fax: 573-756-6807 | |
Dr. George M Gasser Iii, DO Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1105 W Liberty, Suite 2050, Farmington, MO 63640 Phone: 573-701-9600 Fax: 573-701-9605 | |
Hannah Marie Vetter, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1103 W Liberty St, Farmington, MO 63640 Phone: 573-756-6751 |